AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15083437 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight‐bearing supported treadmill gait training augmented by functional electric stimulation (FES) for 25 minutes a day, 5 days a week for 4 weeks
Number of subjects: 14
Study 15083437 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (PT) for 4 weeks
Number of subjects: 14
Study 11444788 — intervention group
Group type: COMPARATOR
Intervention: Continuous dinoprostone
Number of subjects: 118
Study 11444788 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 35-microg suppositories
Number of subjects: 118
Study 11444788 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 50-microg suppositories
Number of subjects: 118
Study 11444788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined misoprostol groups
Number of subjects: 118
Study 9097265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 29
Study 9097265 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 29
Study 9097265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8458802 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral cycling (32-35 degrees C)
Number of subjects: 11
Study 8458802 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warm water exposure (39-41 degrees C)
Number of subjects: 11
Study 8458802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cycling (18-23 degrees C)
Number of subjects: 11
Study 8458802 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest (22 +/- 1 degrees C)
Number of subjects: 11
Study 2870351 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 60881
Study 30714092 — intervention group
Group type: EXPERIMENTAL
Intervention: High hyperdiploid relapses
Number of subjects: 413
Study 30714092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hyperdiploid relapses
Number of subjects: 413
Study 30714092 — intervention group
Group type: EXPERIMENTAL
Intervention: Evident or masked hypodiploid relapses
Number of subjects: 413
Study 30714092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodiploidy
Number of subjects: 413
Study 30714092 — intervention group
Group type: COMPARATOR
Intervention: Current relapse risk stratification
Number of subjects: 413
Study 30041588 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE SMI
Number of subjects: 276
Study 30041588 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMOVE
Number of subjects: 276
Study 30041588 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study 26879036 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPAT (psychosocial pain management intervention)
Number of subjects: 129
Study 26879036 — intervention group
Group type: COMPARATOR
Intervention: SPC (supportive psychoeducational control)
Number of subjects: 129
Study 24682502 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 20
Study 24682502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22588152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 538
Study 22588152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2a patients with KRAS wild-type tumors
Number of subjects: 538
Study 22588152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2a patients with KRAS mutant tumors
Number of subjects: 538
Study 22588152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS wild-type tumors
Number of subjects: 538
Study 22588152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS mutant tumors
Number of subjects: 538
Study 21265908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined student-parent intervention
Number of subjects: 3490
Study 21265908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 3490
Study 21265908 — intervention group
Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 3490
Study 21265908 — intervention group
Group type: COMPARATOR
Intervention: Regular curriculum
Number of subjects: 3490
Study 17873571 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antipyretics
Number of subjects: 0
Study 17873571 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing of indwelling catheters
Number of subjects: 0
Study 17873571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteration in antimicrobial therapy
Number of subjects: 0
Study 17873571 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate measurement of body temperature
Number of subjects: 0
Study 17873571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation
Number of subjects: 0
Study 15955899 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg temsirolimus
Number of subjects: 109
Study 15955899 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg temsirolimus
Number of subjects: 109
Study 12922087 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine administered in one injection
Number of subjects: 235
Study 12922087 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines administered in two simultaneous injections
Number of subjects: 235
Study 12922087 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunogenicity analysis for DTPa-HBV-IPV/Hib
Number of subjects: 235
Study 12922087 — intervention group
Group type: COMPARATOR
Intervention: Immunogenicity analysis for DTPa-IPV/Hib and HBV
Number of subjects: 235
Study 10385357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 23
Study 10385357 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFil Superior
Number of subjects: 23
Study 8672710 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE) approach
Number of subjects: 0
Study 8672710 — intervention group
Group type: EXPERIMENTAL
Intervention: Seemingly unrelated regression paradigm
Number of subjects: 0
Study 1499875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesylate (FOY) 12 mg/kg/day as continuous intravenous infusion for a minimum of 4 days and a maximum of 12 days
Number of subjects: 100
Study 1499875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6580858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 20 mg/kg/day for three consecutive days
Number of subjects: 17
Study 6580858 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone regime
Number of subjects: 17
Study 6580858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 17
Study 6580858 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 17
Study 3534764 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (single drug therapy)
Number of subjects: 44
Study 3534764 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-gentamicin-metronidazole (triple combination)
Number of subjects: 44
Study 31603002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise with blood flow restriction
Number of subjects: 66
Study 31603002 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 66
Study 31603002 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 66
Study 29786702 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (H2O2) gel
Number of subjects: 35
Study 29786702 — intervention group
Group type: COMPARATOR
Intervention: 37.5% hydrogen peroxide (H2O2) gel
Number of subjects: 35
Study 28051341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-compression pressure (HI) group
Number of subjects: 45
Study 28051341 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-compression pressure (LOW) group
Number of subjects: 45
Study 28051341 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound group (SHAM)
Number of subjects: 45
Study 26098729 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31
Study 26098729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23092714 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd-Erns-E2 (2×10(6) TCID(50) administered intramuscularly two times with a 21-day interval)
Number of subjects: 9
Study 23092714 — intervention group
Group type: COMPARATOR
Intervention: hAd-CMV control (3 pigs)
Number of subjects: 9
Study 23092714 — intervention group
Group type: COMPARATOR
Intervention: DMEM control (3 pigs)
Number of subjects: 9
Study 21534640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaborative practice
Number of subjects: 199
Study 21534640 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physician only)
Number of subjects: 199
Study 18162322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise bout (cycling)
Number of subjects: 31
Study 18162322 — intervention group
Group type: EXPERIMENTAL
Intervention: McArdle patients
Number of subjects: 31
Study 18162322 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary controls
Number of subjects: 31
Study 16340480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free virus (CFV)
Number of subjects: 122
Study 16340480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-associated virus (CAV)
Number of subjects: 122
Study 16340480 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV
Number of subjects: 122
Study 16340480 — intervention group
Group type: EXPERIMENTAL
Intervention: CFV
Number of subjects: 122
Study 16340480 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of CFV
Number of subjects: 122
Study 12478111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 2749
Study 12478111 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 2749
Study 12478111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) maintenance
Number of subjects: 2749
Study 10889283 — intervention group
Group type: EXPERIMENTAL
Intervention: vbCBT + paroxetine
Number of subjects: 33
Study 10889283 — intervention group
Group type: COMPARATOR
Intervention: vbCBT + placebo
Number of subjects: 33
Study 9112320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative care (including medications, exercise, injection therapy, and manipulation)
Number of subjects: 0
Study 9112320 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history of disc resorption
Number of subjects: 0
Study 9112320 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation's effect on treatment effectiveness
Number of subjects: 0
Study 9112320 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative versus nonoperative care
Number of subjects: 0
Study 1426660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosomal vaccine (D53)
Number of subjects: 12
Study 1426660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3872688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendosal with food (200 mg)
Number of subjects: 24
Study 3872688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendosal with antacid (200 mg)
Number of subjects: 24
Study 31772157 — intervention group
Group type: EXPERIMENTAL
Intervention: MRM retrieval + ketamine (RET + KET)
Number of subjects: 0
Study 31772157 — intervention group
Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 0
Study 31772157 — intervention group
Group type: COMPARATOR
Intervention: Retrieval alone
Number of subjects: 0
Study 29943508 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with adrenaline 2 μg/mL
Number of subjects: 41
Study 29943508 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia without adrenaline (Control)
Number of subjects: 41
Study 27130166 — intervention group
Group type: COMPARATOR
Intervention: DVD-based training (50 minutes)
Number of subjects: 1232
Study 27130166 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based training (30 minutes)
Number of subjects: 1232
Study 24592958 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care communication provided by physicians-in-training (internal medicine residents and medical subspecialty fellows)
Number of subjects: 0
Study 24592958 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care communication provided by physicians-in-training
Number of subjects: 0
Study 22876304 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meetings intervention (n = 96)
Number of subjects: 192
Study 22876304 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 96)
Number of subjects: 192
Study 20223872 — intervention group
Group type: EXPERIMENTAL
Intervention: Self sampling for high risk HPV testing
Number of subjects: 28073
Study 20223872 — intervention group
Group type: COMPARATOR
Intervention: Recall control group (conventional cytology)
Number of subjects: 28073
Study 18024537 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic spirometry by visiting trained nurses (TN)
Number of subjects: 531
Study 18024537 — intervention group
Group type: COMPARATOR
Intervention: Optimised usual care (UC) from general practitioners (GPs)
Number of subjects: 531
Study 15983674 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 14
Study 15983674 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin (CI) therapy
Number of subjects: 14
Study 12521319 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid for 2 months
Number of subjects: 22
Study 12521319 — intervention group
Group type: COMPARATOR
Intervention: carboxymethylcellulose for 2 months (control)
Number of subjects: 22
Study 12521319 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid for 2 months (after control)
Number of subjects: 22
Study 10434819 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. piritramide (nurse-controlled)
Number of subjects: 60
Study 10434819 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. piritramide (patient-controlled)
Number of subjects: 60
Study 10434819 — intervention group
Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine (nurse-controlled)
Number of subjects: 60
Study 10434819 — intervention group
Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine (patient-controlled)
Number of subjects: 60
Study 7824103 — intervention group
Group type: EXPERIMENTAL
Intervention: Proband with affected parent/aunt/uncle (N = 21)
Number of subjects: 137
Study 7824103 — intervention group
Group type: COMPARATOR
Intervention: Proband with affected sibling only (N = 11)
Number of subjects: 137
Study 7824103 — intervention group
Group type: COMPARATOR
Intervention: Proband with no affected family members (N = 105)
Number of subjects: 137
Study 7824103 — intervention group
Group type: EXPERIMENTAL
Intervention: Generational comparison of age at onset
Number of subjects: 137
Study 2571595 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate (0.25 mg) combined with 0.035 mg ethinyl estradiol (NGM 0.25/35)
Number of subjects: 1261
Study 2571595 — intervention group
Group type: COMPARATOR
Intervention: Lo/Ovral (0.30 mg norgestrel combined with 0.030 mg ethinyl estradiol)
Number of subjects: 1261
Study 565368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sexual role variant
Number of subjects: 24
Study 565368 — intervention group
Group type: COMPARATOR
Intervention: Inadequate sexual role variant
Number of subjects: 24
Study 31088392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin Pro (gel-based emulsion)
Number of subjects: 0
Study 31088392 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun® Optoral (microemulsion)
Number of subjects: 0
Study 30077678 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 200
Study 30077678 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 200
Study 26987755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT) for two hours a day for three months
Number of subjects: 100
Study 26987755 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study 26987755 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scales
Number of subjects: 100
Study 25038015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 67
Study 25038015 — intervention group
Group type: COMPARATOR
Intervention: Decubitus Position (DP)
Number of subjects: 67
Study 22666385 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Review (PR) treatment
Number of subjects: 0
Study 22666385 — intervention group
Group type: COMPARATOR
Intervention: Non-Peer Review (non-PR) treatment
Number of subjects: 0
Study 19617318 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-flutemetamol
Number of subjects: 16
Study 17503661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient combination antiretroviral treatment (CART)
Number of subjects: 79
Study 15469659 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond supplementation (52 g/d) for 6 months
Number of subjects: 81
Study 11462182 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc bacitracin (n=6)
Number of subjects: 12
Study 11462182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=6)
Number of subjects: 12
Study 10091160 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide administration
Number of subjects: 33
Study 10091160 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise (Control)
Number of subjects: 33
Study 7818923 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antithyroid antibodies (ATA) in gastric cancer patients
Number of subjects: 32
Study 7818923 — intervention group
Group type: COMPARATOR
Intervention: Presence of antithyroid antibodies (ATA) in healthy controls
Number of subjects: 32
Study 7818923 — intervention group
Group type: COMPARATOR
Intervention: Presence of antithyroid antibodies (ATA) in patients with other malignant tumours (OMT)
Number of subjects: 32
Study 7818923 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid function in patients with ATA
Number of subjects: 32
Study 7818923 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ATA and chronic gastritis
Number of subjects: 32
Study 7818923 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ATA incidence between GC patients and controls
Number of subjects: 32
Study 3259104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 micrograms intravenously before induction
Number of subjects: 50
Study 3259104 — intervention group
Group type: COMPARATOR
Intervention: No sedative or analgesic drugs (Control)
Number of subjects: 50
Study 28437029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vegetable diet intervention
Number of subjects: 478
Study 28437029 — intervention group
Group type: COMPARATOR
Intervention: Control condition (diet counselling intervention)
Number of subjects: 478
Study 26604214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost (2.0 ng/kg/min) continuous infusion for 72 hours postoperatively
Number of subjects: 27
Study 26604214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 27
Study 24554548 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil/propofol (RP)‐TIVA
Number of subjects: 77
Study 24554548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine/propofol (DP)‐TIVA
Number of subjects: 77
Study 22913908 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 20 mg (fasted)
Number of subjects: 40
Study 22913908 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg (fasted)
Number of subjects: 40
Study 22913908 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 50 mg (fasted)
Number of subjects: 40
Study 22913908 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg (fed)
Number of subjects: 40
Study 22913908 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 50 mg (fed)
Number of subjects: 40
Study 22913908 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg and indomethacin 50 mg
Number of subjects: 40
Study 22913908 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin and standard indomethacin
Number of subjects: 40
Study 20727331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus ginsenosides
Number of subjects: 60
Study 20727331 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus placebo
Number of subjects: 60
Study 17912939 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 50
Study 17912939 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 50
Study 15788469 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin‐alpha (DA) administered subcutaneously weekly
Number of subjects: 162
Study 15788469 — intervention group
Group type: COMPARATOR
Intervention: Epoetin‐beta (EB) administered subcutaneously weekly
Number of subjects: 162
Study 12198060 — intervention group
Group type: EXPERIMENTAL
Intervention: True points acupressure
Number of subjects: 60
Study 12198060 — intervention group
Group type: COMPARATOR
Intervention: Sham points acupressure
Number of subjects: 60
Study 12198060 — intervention group
Group type: COMPARATOR
Intervention: No acupressure
Number of subjects: 60
Study 8765425 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3 at 5 or 10 micrograms/kg per day on days 4-13 after chemotherapy
Number of subjects: 41
Study 8765425 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no rhIL-3)
Number of subjects: 41
Study 2109926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 clot‐lysis megaunits (cIMU) double‐chain rt‐PA over 1.5 hours followed by 20 cIMU over 5 hours (infusion group, n = 12)
Number of subjects: 26
Study 2109926 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 intravenous bolus injections of 10 cIMU at 20 minute intervals (bolus group, n = 14)
Number of subjects: 26
Study 2109926 — intervention group
Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 26
Study 2109926 — intervention group
Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 26